Nevertheless, further ER stress stimulation in NOTCH1-deregulated CLL might represent an additional therapeutic opportunity for these high-risk patients and improve the therapeutic effect of drugs currently used in CLL. This evidence concerns the gene NOTCH1 and B-cell chronic lymphocytic leukemia.